A Drug Information Association Workshop on "Statistical Methodology on Non-Clinical and Toxicological Studies" was held March 25-27, 1996
THE PROBLEM
IN PHARMACOLOGY animal studies can be categorized as screening studies for a series of substances on a well-defined animal model in which the outcome is frequently dichotomous (eg, responderhonresponder), standardized bioassay for estimation of biological activity, and studies to demonstrate a clinically relevant effect for a selected substance in a specific-sometimes not established-animal model, usually based on a design "treatment or dose groups versus negative control." The last type of study will be considered here. The paradigm of these studies is similar to clinical trials: randomized, placebo (negative control C-) controlled, based on experimental design with sample size estimation, definition of an (clin- ical) endpoint, and using a standardized protocol and analysis.
Frequently for these studies, a stepwise testing scheme can be observed: starting with a small sample size pilot study, continuing with a larger sample size extended pilot study, and decision making by a final perprotocol study. The reasons for this stepwise procedure are:
The clinically relevant endpoint is unknown a priori. This primary endpoint should be selected from some candidates using this study, The variance CJ is unknown a priori. The same problem occurs in clinical trials as described by Gould (2), The relevant effect difference 6 (either to negative control or to a competitor's drug) is unknown a priori, The effective dose is unknown a priori in dose-finding studies, and *The relevant time is unknown a priori within the usually repeated measurements.
In the real data situation two approaches seem to be possible: 1. Learning from pilot studies and designing the per-protocol study using this information, however, rejecting the pilot studies from the direct final decision making, and 2. Definition of an "internal" pilot study.
Here, the concept of "adaptive interim analysis" according to Bauer and Kohne (1) will be used considering the information from the pilot study directly into the test decision.
ADAPTIVE INTERIM ANALYSIS
The principle of the adaptive interim analysis according to Bauer and Kohne (1) is as follows:
Two independent randomized studies are to be performed: pilot and second ("main") study, 0 Use all suitable information from the small sample size (undesigned) pilot study to adapt the second (main) study for new design and sample size: relevant endpoint, relevant dose group, relevant time point, relevant effect difference 6, variance 6, pvalue of the first pilot study pl, and so forth, Combine both studies to a global result by Fisher's product criterion based on both p-values: plp2 I c, (with pi . . . p-value of the i" study with i E (1, 2) [An extension to i = 3 is given in Bauer and Kohne (1) too]). That means that the null-hypothesis of no effect will be rejected, if the product of both p-values is smaller than a predefined critical value c,. The critical value c, was determined by Bauer and Kohne (1) as a modification of Fisher's product criterion taking the early stopping rules due to ineffectiveness or effectiveness in the first study into account, and 0 Use early stopping rules: due to ineffectiveness, if pI > supper , then & is accepted; respective due to effectiveness, if pl < slower, then Ho is rejected, otherwise adapt the sec-ond study. For an experimentwise type I error rate ae,,=0.05 possible values for aUpPer and slow,, are given in Table 1 according to Bauer and Kohne (1) .
A practical choice for pharmacological studies could be aUpFr=0.5 (decision for early stopping due to ineffectiveness if the effect tends in the wrong direction) and based on c, = 0.0087 a level for slower = 0.0233 results. An extension to three studies is given in Bauer and Kohne (1) but should not be discussed here.
Two questions arise for this approach; how large is the loss of power of this twostep approach in comparison with a one-step uniformly most powerful test and which price must be paid for this approach? The first question was answered by Banik et al.
(3): the loss of power is practically negligible down to Nglobd = nl + n2 = 12. Therefore, an application in pharmacological studies is not limited. The price to be paid is:
A combination of p-values instead of pool-
ing the data, that is, two independent studies still exist, also for descriptive statistics, but not a unique study with pooled data, 2. More than double time is necessary, and 3. Only the intersection of both hypotheses Hol f l HO2 can be rejected and, therefore, the interpretation is possible only for this intersection according to Bauer and RSh-me1 (4) .
Several adaptations exist for the second study: [5] ),
The primary endpoint with the objective to reduce the number of multiple endpoints, for example, using multiple endpoint tests of different dimensions in the pilot and main study, Dose groups with the objective to select the "best" and reduce the number of dose Dose steps: increase or decrease the distances between dose levels, Time points with the objective to select the "best" and reduce the number of time points, and The type of test statistics, for example, ttest in the primary and u-test in the secondary study after a heavily-skewed distribution was observed in the pilot study.
groups (see [41),
This list indicates that this approach is very flexible in adaptation because it is based on two independent randomized studies with their p-values only. The adaptations are primarily restricted by the interpretation of the outcome of Fisher s product criterion consisting of different tests in the first and secondary studies.
APPLICATION IN PHARMACOLOGY
In comparison with clinical trials, adaptive interim analysis can be easily used in pharmacology because of less serious problems with unblinding; short-term studies, where the doubling of time is not too critical; and imental question was two-sided, that is, for a difference of blood loss. The decision on an appropriate two-sample test for this data is not simple. Because of small sample sizes and unknown distribution, a permutative Utest was used, although heterogeneity of variance exists. Table 2 presents the raw data for the undesigned internal pilot study.
Analyzing this data by StatXact (7), a pvalue p, = 0.132 for the permutative U-test results. The following conditions for adaptive interim analysis were used (see Table 1 ): a, = 0.5, alawer = 0.0233 and c, = 0.0087. Because p, = 0.132 is smaller than 0.5 and larger than 0.0233 no early stopping can be performed based on this pilot study. Therefore, sample size should be estimated for the second study. Sample size estimation was approximately performed for the asymptotic Utest using Noether's (8) approach. From this pilot study a variance estimation of 6' = 2250000 was assumed. Based on the predefined type I1 error p = 0.20 and the relevant effect difference defined a-priori based on medical information of 6 = 2800, sample sizes of nZi = 5 were estimated for the local size of the second study p2 = 0.066, based on From the raw data of the second study a p-value of p2 = 0.0434 was estimated. Because of pI*p2 = 0.0057 < c, the global decision is that Protease reveals a significantly different blood loss in comparison to Alteplase. Moreover, two independent randomized studies demonstrate an effect in the same direction. 8.78, 8.97, 8.0, 4.78, 9.72, 11.18, 16.49,15.61,11.14,9.3,7.56,12.81,   72, 72, 20, 68, 72, 72, 72, 72   8.91, 8.47  8.19, 7.44   38, 41, 72, 72, 72, 34, 48.5, 24 lung weight, using a subacute primate model of hypovolemic-traumatic shock with a threeday observation period (9) . One-sided tests (increase of survival time and decrease of lung weight) should be performed in a multiple endpoint analysis. Table 3 presents the raw data for the undesigned internal pilot study.
Using rank transformed multiple endpoint analysis according to O'Brien (10) a p-value p1 = 0.145 was estimated. The univariate p-values: survival time Plogrankfest = 0.086 and lung weight pu.test = 0.399 indicated that the more sensitive endpoint is survival time. Therefore, the test statistics were changed: from the multiple endpoint analysis containing both endpoints in the pilot study to the univariate test on survival time only (using logrank test) in the second study.
The same conditions for adaptive interim analysis as in example 1 were used (see Table   1 ): a, = 0.5, slower = 0.0233 and c, = 0.0087.
No early stopping is possible. Therefore, sample size should be estimated for the second study, resulting in n2i = 5. The second study revealed a p-value: p2,survival time = 0.027 1. Because of p1*p2 = 0.0039 < c, = 0.0087 Anti-L-Selectin reveals a significant effect over placebo. Moreover, two independent randomized studies demonstrate an effect in the same direction.
CONCLUSIONS
Adaptive interim analysis represents a new technique in the case of uncertainty to make a clear decision: significantlnonsignificant effects. It is adapted to the experimental paradigm of pharmacologists: stepwise. Using this principle, one methodological dilemma can be overcome by answering the question in case of a nonsignificant study: "Is the substance ineffective or was the study design invalid, for example, was the sample size too small?" The application of adaptive interim analysis seems to be simpler in preclinical studies than in clinical trials because of fewer problems with study protocols and unblinding.
A price must be paid, however, for using this approach: combination of p-values instead of pooling the data, increase of necessary time, and interpretation of the intersection of both hypotheses only. To avoid abuse, in the study protocol the kind of adaptations to be intended should be fixed a priori.
Summarizing, adaptive interim analysis is a simple approach, frequently easy for pharmacologists to perform; only one table is needed (eg, Table l), as well as p-values from usual tests, that is, t-or U-tests.
